Abstract:e20504 Background: There are significantly differences in the efficacy of platinum based chemotherapy in NSCLC patients. Platinum leads to the cell death by damaging DNA through the chain cross link or chain cross-linking of DNA.Base excision repair (BER) plays an important role in the maintenance of genome integrity and anti-cancer drug resistance. There are a few researches on whether BER can influence the sensitivity of platinum-based chemotherapy, while the sample size is small and the influencing factors are poorly controlled, which needs further verifying. We eager to explore the role of BER genes polymorphisms in response to chemotherapy of advanced non small-cell lung cancer (NSCLC) patients treated with platinum-based chemotherapy. Methods: During the period from November 2009 to January 2016, a total of 152 patients diagnosed with IIIB or IV stage NSCLC in the First Hospital of Jilin University were admitted into our study who were treated with platinum-based chemotherapy. The XRCC1 G28152A, MUTYH G972C, HOGG1 C1245G, PARP1 T2444C polymorphisms of all the patients were detected by the mass spectrometry. And use the Logistic regression to analysis the relationship between the BER genes polymorphisms and the curative effect of platinum-based chemotherapy. Results: The effective rates of chemotherapy in patients with PARP1 2444 TT, CC and TC genotype were 9/44 (20.5%), 15/28 (53.6%) and 28/76 (36.8%) respectively. Logistic regression model showed that the effective rate of chemotherapy of the PARP1 T2444C polymorphisms, CC genotype (OR: 5.216, 95%CI: 1.568-17.352, P= 0.007) and TC genotype (OR: 2.692, 95%CI: 1.007-7.198, P= 0.048) are significantly higher than the TT wild type, as well as the genotype of TC together with CC (OR: 3.178, 95%CI:1.229-8.219, P = 0.017). There is no relationship between G28152A, MUTYH G972C, XRCC1 HOGG1 C1245G gene polymorphism and chemosensitivity. Conclusions: PARP1 2444 mutation allele C might be associated with the decreased sensitivity to platinum based chemotherapy in advanced NSCLC. Our findings may be helpful towards designing individualized cancer treatment.

Association Between Polymorphisms of Ercc1 and Xpd and Clinical Response to Platinum-Based Chemotherapy in Advanced Non-Small Cell Lung Cancer

Association of Base Excision Repair Gene Polymorphisms with the Response to Chemotherapy in Advanced Non-Small Cell Lung Cancer

A Meta-Analysis Identifies ERCC1 Gene Polymorphism As a Predictor of Better Patient Response to Treatment with Radiochemotherapy

Effect of Polymorphisms in Xpd on Clinical Outcomes of Platinum-Based Chemotherapy for Chinese Non-Small Cell Lung Cancer Patients

Single Nucleotide Polymorphisms in XRCC1 and Clinical Response to Platin-based Chemotherapy in Advanced Non-small Cell Lung Cancer

Genetic Variants in ERCC1 and XPC Predict Survival Outcome of Non-Small Cell Lung Cancer Patients Treated with Platinum-Based Therapy

Single Nucleotide Polymorphism in ERCC1 118C→T Predicts the Outcome of NSCLC Patients Receiving Platinum-Based Chemotherapy

Study on ERCC1,XPD and XPA Polymorphisms for Prediction of Platinum-Based Chemotherapy Sensitivity in Non-Small Cell Lung Cancer

Genetic Polymorphisms and Treatment Response in Advanced Non-Small Cell Lung Cancer.

Predictive value of ERCC1 and XPD polymorphism in patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy: a systematic review and meta-analysis

Single nucleotide polymorphisms in XRCC1,XPD and platinum prognosis in non-small-cell lung cancer patients

Methylenetetrahydrofolate Reductase C677T Polymorphism Predicts Response and Time to Progression to Gemcitabine-Based Chemotherapy for Advanced Non-Small Cell Lung Cancer in a Chinese Han Population

Single nucleotide polymorphisms of nucleotide excision repair pathway are significantly associated with outcomes of platinum-based chemotherapy in lung cancer

Genetic Polymorphism of ERCC1 and XRCC1 Correlated with Response to Oxaliplatin Based Chemotherapy in Advanced Colorectal Cancer

Association Of Base Excision Repair Gene Polymorphisms With Response To Chemotherapy Of Advanced Non Small-Cell Lung Cancer In A Chinese Population.

Polymorphisms in the base excision repair pathway modulate prognosis of platinum-based chemotherapy in advanced non-small cell lung cancer

Predictive value of base-excision repair gene polymorphisms in advanced non-small cell lung cancer patients receiving platinum-based chemotherapy

Protein Expression Levels Of Excision Repair Cross-Complementation Group 1 And Xeroderma Pigmentosum D Correlate With Response To Platinum-Based Chemotherapy In The Patients With Advanced Epithelial Ovarian Cancer

An ERCC4 Regulatory Variant Predicts Grade-3 Or-4 Toxicities in Patients with Advanced Non-Small Cell Lung Cancer Treated by Platinum-Based Therapy

Single-arm, open label prospective trial to assess prediction of the role of ERCC1/XPF complex in the response of advanced NSCLC patients to platinum-based chemotherapy

Role of rs873601 Polymorphisms in Prognosis of Lung Cancer Patients Treated with Platinum-Based Chemotherapy